Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Medtronic
Dow
Express Scripts
Mallinckrodt

Last Updated: November 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for SGN-15

See Plans and Pricing

« Back to Dashboard

What is the drug development status for SGN-15?

SGN-15 is an investigational drug.

There have been 71 clinical trials for SGN-15. The most recent clinical trial was a Phase 2 trial, which was initiated on April 1st 2010.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Non-Hodgkin, and Hodgkin Disease. The leading clinical trial sponsors are Seattle Genetics, Inc., Millennium Pharmaceuticals, Inc., and Genentech, Inc.

There are two US patents protecting this investigational drug and thirteen international patents.

Recent Clinical Trials for SGN-15
TitleSponsorPhase
A Study of SGN-CD228A in Advanced Solid TumorsSeattle Genetics, Inc.Phase 1
A Safety Study of SGN-CD47M in Patients With Solid TumorsSeattle Genetics, Inc.Phase 1
BrEPEM-LH-22017 for Older Patients With Untreated Hodgkin Lymphoma (HL)TakedaPhase 1/Phase 2

See all SGN-15 clinical trials

Clinical Trial Summary for SGN-15

Top disease conditions for SGN-15
Top clinical trial sponsors for SGN-15

See all SGN-15 clinical trials

US Patents for SGN-15

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGN-15   Start Trial Compositions and methods for cancer immunotherapy Eisai R&D Management Co., Ltd. (Bunkyo-Ku, Tokyo, JP)   Start Trial
SGN-15   Start Trial Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents Massachusetts Institute of Technology (Cambridge, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGN-15

Drugname Country Document Number Estimated Expiration Related US Patent
SGN-15 Australia 2006241206 2025-04-26   Start Trial
SGN-15 Canada 2605749 2025-04-26   Start Trial
SGN-15 China 101355928 2025-04-26   Start Trial
SGN-15 China 103285392 2025-04-26   Start Trial
SGN-15 European Patent Office 1874342 2025-04-26   Start Trial
SGN-15 Japan 2008539249 2025-04-26   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Johnson and Johnson
Boehringer Ingelheim
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.